Thyroid

[Tricia13]

Can anyone tell me if brand name ELTROXIN is a good tablet. Or is Aristo a brand or generic pls

[helvella Administrator Thyroid UK]

Mercury Pharma Eltroxin is absolutely identical to Mercury Pharma levothyroxine. And Mercury Pharma is part of Advanz.

It is, simply, one of the available products. As with all of them, if it suits you, it is good, if it doesn't, it is bad.

Aristo is another make - available in 100 microgram tablets only.

I have created, and try to maintain, a document containing details of all thyroid hormone medicines in the UK and many in other countries.

helvella - Thyroid Hormone Medicines.pdf

This document has information about the available thyroid hormones in the UK and, in less detail, around the world.

dropbox.com/s/shcwdwpedzr93...

The generic vs. brand discussions so common from USA sources really don't apply the same in the UK. Virtually all levothyroxine is prescribed as the generic active ingredient. But virtually all levothyroxine is dispensed in branded packaging with full details of the company and product.

I'm not sure why you are asking, so my attempt to reply might not have addressed your needs. Please amplify and clarify if it doesn't.

[meki]

I understood from my endo back in 1980's ELTROXIN is the generic.

[helvella Administrator Thyroid UK in reply to meki]

In 1951, in the UK, Glaxo decided to call their levothyroxine product, l-thyroxine-sodium, by the branded name "Eltroxin".

In 1954, in the UK, Glaxo applied for the trade mark "Eltroxin".

Between about 1990 and 1995, in the UK the trade mark "Eltroxin" appeared to have been handled by Evans Medical (Medeva) before being acquired by Goldshield.

In the UK, the trade mark "Eltroxin" remains with the successors to Goldshield - Mercury Pharma (now part of Advanz) through rebranding, acquisitions and mergers (company names including Amdipharm and Concordia were involved).

The trade mark "Eltroxin" in most of the rest of the world remained with Glaxo, eventually GlaxoSmithKline. (Ireland and India appear to have been a special cases.)

In 2008, GlaxoSmithKline sold worldwide rights to "Eltroxin" (except in the UK and a few other exceptions) to Aspen. They also acquired an 18% stake in Aspen. At the same time, the location of the manufacturing plant and the formulation of GlaxoSmithKline/Aspen "Eltroxin" changed significantly.

Aspen supply "Eltroxin" in many countries.

Further details:

Now Under Trade Name.—Glaxo Lab-

oratories, Ltd., Greenford, Middlesex, an-

nounce that I-thyroxine-sodium, Glaxo, is

now supplied in both strengths under the

trade name Eltroxin. There is no change

in packs or prices.

The chemist and druggist [electronic resource]

By UBM

Publication date 1951

Topics Pharmacy, Drug Industry

Publisher London : Morgan Brothers

archive.org/details/b199747...

1954/05/25

TM Eltroxin Trademark Eltroxin registered in UK. Registration No. 730598 for the trade mark ELTROXIN was applied for in the name of Glaxo Laboratories Ltd. trademarks.ipo.gov.uk/ipo-t... ipo.gov.uk/t-challenge-deci...

1992/02/01 Medeva are taking over responsibility for the sale of 30 Glaxo brands (52 product lines) in the UK. These include Eltroxin. They will be marketed by Evans Medical

1992/12/03

PL

Evans acquire Eltroxin in UK

PL 0039/0430

Evans Medical Limited

Eltroxin Tablets 50 micrograms

Thyroxine Sodium BP 0.056 mg

Prescription Only Medicine

3rd December 1992

PL 0039/0431

Evans Medical Limited

Eltroxin Tablets 100 micrograms

Thyroxine Sodium BP 0.112 mg

Prescription Only Medicine

3rd December 1992

thegazette.co.uk/Belfast/is...

2008/07/02 CO GSK signs product deal with Aspen

Date Type Occurrence GlaxoSmithKline has announced that it is selling four products - Eltroxin, Lanoxin, Imuran and Zyloric - to a subsidiary of South African-based pharmaceuticals group, Aspen Global, for a cash consideration of £170m. GlaxoSmithKline (GSK) has announced that it is selling four products - Eltroxin, Lanoxin, Imuran and Zyloric - to a subsidiary of South African-based pharmaceuticals group, Aspen Global, for a cash consideration of £170m. Aspen will take ownership of the four products, which require specialised manufacturing, in all major markets outside the US, except for rights to Zyloric in Japan. Total sales for all four branded medicines, which largely no longer hold patent protection, were around £80m in 2007 in the markets concerned with the agreement. pmlive.com/pharma_news/gsk_...

[meki]

Thank you for this. Very Interesting